Study of Livmarli for Alagille Syndrome and PFIC

This study creates a registry to track children with specific genetic liver conditions that cause cholestasis (slow bile flow). Being in the registry helps researchers better understand these diseases and may help future patients.

This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.

This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.

This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.

This trial tests a medicine called maralixibat to see if it helps children with cystic fibrosis who have chronic constipation that doesn't improve with standard treatments. The goal is to improve bowel movements and quality of life.

This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.